File downloaded on 2025-12-24

Source URL: https://medicines.health.europa.eu/veterinary/en/600000051683

Selames 240 mg spot-on solution for dogs 20.1–40.0 kg

Authorised

Selamectin

Product identification

Medicine name:

Selames 240 mg spot-on solution for dogs 20.1–40.0 kg Selames voor honden 20,1-40,0 kg 240 mg Spot-on oplossing Selames pour chiens 20,1-40,0 kg 240 mg Solution pour spot-on Selames fur Hunde 20,1-40,0 kg 240 mg Lösung zum Auftropfen

Active substance:

Selamectin

Target species:

Dog

Route of administration:

Spot-on use

Product details

Active substance and strength:

Selamectin 240.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:

Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AA05

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Belgium

Package description:

Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. Cardboard box containing 1 pipette. Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. Cardboard box containing 3 pipettes. Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. Cardboard box containing 6 pipettes. Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. Cardboard box containing 15 pipettes.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Marketing authorisation date:

7/12/2018

Manufacturing sites for batch release:

TAD Pharma GmbH

KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:

Federal Agency For Medicines And Health Products

Authorisation number:

BE-V537093

Date of authorisation status change:

7/12/2018

Reference member state:

Ireland

Procedure number:

IE/V/0407/004

Concerned member states:

Belgium France Germany Italy Netherlands Portugal Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 3/05/2024

Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.